NeuroOne regains Nasdaq compliance; reports record preliminary Q1 revenue of $6.2M

NEUROONE MEDICAL TECHNOLOGIES Corp

Received Nasdaq letter on Feb 3, 2025 confirming cure of bid price deficiency; hearing cancelled.
Preliminary unaudited Q1 FY2025 total revenue of $6.2M (product $3.2M + one-time license $3.0M).
CEO highlights OneRF Ablation System as first FDA-cleared device for RF ablation in the brain.
Earnings call scheduled for February 12, 2025 at 8:30 am ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.